Researchers report that patients with advanced cutaneous squamous cell carcinoma, a skin cancer and one of the most frequent malignancies worldwide, benefit from treatment with the immune checkpoint… read more.
The study, published today in the Journal of Medical Screening, found that issuing pre-booked appointments, rather than invitations to book an appointment, could lead to substantially greater uptake of… read more.
Researchers reported a 20 percent advantage in the two-year overall survival rate for subjects with advanced melanoma and a mutation in the BRAF gene, specifically a BRAF V600 mutation, who were initially… read more.
A research team from the Centre for Safe Medication Practice and Research (CSMPR), Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong (HKUMed)… read more.
New study data shows that the immuno-oncology drug, atezolizumab (pronounced a” te zoe liz’ ue mab, marketed as Tecentriq) is a safe and effective treatment for stage IB-IIIB… read more.
A new study led by University of Ottawa professors has found Canadian provinces that annually screen women aged 40-49 had lower proportions of advanced breast cancer compared to… read more.
Lung cancer, the most common cancer worldwide, is targeted with radiation therapy (RT) in nearly one-half of cases. RT planning is a manual, resource-intensive process that can take… read more.
(7 September 2022, Milan, Italy) 8 in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented… read more.
A research team from the lab of Quing Zhu, the Edwin H. Murty Professor of Engineering in the Department of Biomedical Engineering at the McKelvey School of Engineering… read more.
Recent research indicates that during the first year of the COVID-19 pandemic, the proportion of working-aged U.S. adults without health insurance did not change despite increases in unemployment,… read more.
In England, 37 people die each day from bowel cancer, but screening using faecal blood testing followed by a colonoscopy can reduce both the incidence of this cancer… read more.
In a Phase I/II trial, cancer treatment with pralsetinib has produced high response rates in patients with RET gene fusions, regardless of tumor type, researchers reported on Aug.12,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
